Researchers fear that breakthroughs from abroad are going to be too slow or inequitably shared to profit the worldwide south.
Gustavo Cabral de Miranda is employed by people doubting him. As a child, he often had to place his schoolwork on hold to assist his family, selling frozen dessert and mangoes at fairs or performing at a butcher’s shop in Bahia, in northeastern Brazil. By the time he decided, at 22 years old, to prevent this work and study to become a scientist, others were telling him that academic life wouldn't suit him: “It wasn’t for people like me,” he remembers them saying.Now, Cabral, an immunologist at the University of Sao Paulo, is one among a variety of ambitious Latin American scientists who are forging ahead with vaccine research programs to fight COVID-19.
Right now, there's no vaccine for the coronavirus that causes the disease. A select group of candidates, most of them supported by pharmaceutical companies in China, the us, and Europe, have entered trials in humans. But researchers like Cabral need a back-up plan, just in case these well-resourced front runners aren't successful, or hoarding of international deal-making prevents them from reaching low- and middle-income countries. Their goals echo long-standing efforts throughout Latin America to maximize national knowledge and establish — or re-establish — scientific independence from overseas pharmaceutical companies.
On the front lines of the coronavirus-vaccine battle
As Latin America becomes the new epicenter of COVID-19, concerns are flaring about the prospect of counting on a vaccine developed and made elsewhere, especially as long as rich countries have had better access to vaccines in the past1. “We’ve already seen some monopoly behavior, even though we don’t have a COVID-19 vaccine yet,” says Gavin Yamey, a global-health researcher at Duke University in Durham, North Carolina. Some governments of high-income countries have reportedly tried to shop for vaccine-manufacturing companies or acquire a percentage of their supply.
“The only ones who are getting to solve the issues in Latin America are getting to be us, Latin Americans. No one’s coming to rescue us,” says María Elena Bottazzi, a Honduran microbiologist at Baylor College of Drugs in Houston, Texas, who’s developing a COVID-19 vaccine that she plans to distribute throughout the region by partnering with local vaccine-producing hubs, like Mexico, Brazil, and Argentina.
Some groups are performing on ensuring equitable access, but billions of doses are going to be needed worldwide and no single provider can supply that quantity, says Fernando Lobos, a director at Sinergium Biotech, a vaccine maker in Buenos Aires.
Instead of waiting to ascertain what happens, researchers across Latin America are working to seek out their answer to the pandemic. “It does not matter if we start with fewer funds, but rather that we start,” says Cabral.
Betting on innovation in Brazil
Cabral returned to Brazil in November 2019, after five years in Europe learning about new vaccine technologies. He was performing on vaccines against the bacterium Streptococcus pyogenes and therefore the Chikungunya virus, which both cause tons of illness in Brazil – when COVID-19 began spreading rapidly across the globe. “I had to quickly adapt the project,” he says.
The race for coronavirus vaccines: a graphical guide
His team uses harmless, hollow, virus-like particles created within the lab. The researchers stud the surfaces of those particles with fragments of the proteins that the coronavirus uses to enter human cells; the thought is to trick the system into producing antibodies that might block the coronavirus during an infection.
Because these particles can’t replicate inside the physical body, they’re considered safer than vaccines made up of weakened viruses, and therefore the technology has been wont to create commercially available vaccines for hepatitis B and human papillomavirus. Cabral’s group is starting animal testing, and some other COVID-19 vaccine candidates in the preclinical evaluation are following a similar approach.
Cabral thinks Brazil would be ready to produce a secure and effective vaccine on an outsized scale and distribute it throughout the state and to neighboring countries. The country is one of the most important vaccine producers in Latin America. Over the past several decades, it's introduced improved technologies, trained pioneering scientists, and developed the foremost diverse vaccine portfolio within the region — even exporting to other nations.
Luciana Leite, a vaccinologist at the Butantan Institute in Sao Paulo, says that innovation is vital. The world will need alternatives if vaccine candidates using conventional approaches fail. “If you have an idea that’s different from what’s out there, I think it’s worthwhile contributing with that,” she says.
If a coronavirus vaccine arrives, can the planet make enough?
Her approach is predicated on the property of some bacteria that release tiny bubbles, or vesicles, from their membranes to mislead a host’s system. Researchers have tried to harness these vesicles to hold viral proteins — antigens that the system can recognize and make antibodies against — mixing them to trigger a response. In as-yet-unpublished research, Leite and her students have found how to connect large amounts of antigens to the bubbles, inducing a stronger-than-usual immune reaction. They are now using an equivalent technique with proteins from the coronavirus SARS-CoV-2.
Cabral hopes that all these efforts will show Brazilians that the government should invest more in research, which has been hit by budget cuts in recent years, sparking an exodus of young scientists. The COVID-19 pandemic is the right moment, he says.
“This is the best time to open our eyes,” Cabral says. “When the dust settles, priorities change.”
Hi friends. I am M Aliyan and in this blog i am going to share articles about Nature and Journals of Nature. I also Post Latest News of all world.
If You have any doubt, you can share.
Don't spam plz ConversionConversion EmoticonEmoticon